{"doi":"10.1053/j.seminoncol.2006.10.007","title":"Is There a Third-Line Therapy for Metastatic Colorectal Cancer?","abstract":null,"journal":"Seminars in Oncology","year":2006,"id":604564,"datarank":1.0345167209437047,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"self_citation_contribution":0.3596842909197557,"citation_network_contribution":0.6748324300239491,"self_endowment_contribution":0.3596842909197557,"citer_contribution":0.6748324300239491,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":10,"citers_with_citation_signal":10,"citers_with_endowment":10,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1551207,"name":"A GROTHEY","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Is There a Third-Line Therapy for Metastatic Colorectal Cancer?","abstract":"Selection of third-line treatment in metastatic colorectal cancer depends on the agents that have been used in prior therapy. A principle in treatment is to use all five of the active drugs in this setting (5-fluorouracil [5-FU], oxaliplatin, irinotecan, cetuximab, and bevacizumab) during the patient's overall treatment course for metastatic disease because cumulative use of available active drugs appears to increase overall survival. Currently, 5-FU/leucovorin (5-FU/LV)/oxaliplatin (FOLFOX) or 5-FU/LV plus irinotecan (FOLFIRI) can be considered standard therapy in first-line treatment, with cross-over irinotecan or oxaliplatin-containing regimens as a component of several possible second-line regimens. On this scenario, third-line treatment can include the combination of irinotecan with cetuximab or bevacizumab or both or the use of cetuximab and bevacizumab in combination. Data from randomized trials on third-line treatment are needed.","is_dataset_classified":null,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"17178284","pmcid":null,"openalex_id":"https://openalex.org/W1991332977","authors":[],"funders":[],"total_grants":0,"fwci":0.7397,"citation_percentile":0.69370851,"influential_citations":0,"citation_trend":[{"year":2017,"count":1},{"year":2019,"count":1},{"year":2023,"count":1}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0093775406003848?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0093775406003848?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1053/j.seminoncol.2006.10.007","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/17178284","host_type":"repository"}],"fields_of_study":["Colorectal Cancer Treatments and Studies","Gastric Cancer Management and Outcomes","Cancer Treatment and Pharmacology"],"mesh_terms":["Adenocarcinoma","Antineoplastic Combined Chemotherapy Protocols","Humans","Colorectal Neoplasms"],"keywords":["Irinotecan","Medicine","Cetuximab","Bevacizumab","Oxaliplatin","FOLFIRI","Colorectal cancer","Oncology","FOLFOX","Internal medicine","Chemotherapy","Cancer"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T00:25:01.933499Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}